{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T06:22:23Z","timestamp":1766211743842,"version":"3.48.0"},"reference-count":27,"publisher":"Japan Neurosurgical Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol. Med. Chir.(Tokyo)"],"published-print":{"date-parts":[[2025,12,15]]},"DOI":"10.2176\/jns-nmc.2025-0190","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:08:37Z","timestamp":1760998117000},"page":"599-606","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Clazosentan Use on Symptomatic Vasospasm and Early Ambulation in Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Cohort Study"],"prefix":"10.2176","volume":"65","author":[{"given":"Satoshi","family":"SUZUKI","sequence":"first","affiliation":[{"name":"Department of Physical Rehabilitation, Akita Prefectural Cardiovascular and Neurosurgical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"SETO","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita Prefectural Cardiovascular and Neurosurgical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junta","family":"MOROI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Akita Prefectural Cardiovascular and Neurosurgical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) van Gijn J, Kerr RS, Rinkel GJE. Subarachnoid haemorrhage. Lancet. 2007;369 (9558):306-18. doi: 10.1016\/S0140-6736(07)60153-6","DOI":"10.1016\/S0140-6736(07)60153-6"},{"key":"2","unstructured":"2) Dorsch NW. Neurological deterioration after subarachnoid haemorrhage. Lancet Neurol. 2002;1 (2):86-96."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Weir B, Grace M, Hansen J, et al. Time course of vasospasm in man. J Neurosurg. 1978;48 (2):173-8. doi: 10.3171\/jns.1978.48.2.0173","DOI":"10.3171\/jns.1978.48.2.0173"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4) Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2012;43 (6):1711-37. doi: 10.1161\/STR.0b013e3182587839","DOI":"10.1161\/STR.0b013e3182587839"},{"key":"5","unstructured":"5) Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan, an endothelin receptor antagonist, in aneurysmal subarachnoid hemorrhage. Expert Opin Investig Drugs. 2007;16 (11):1769-77."},{"key":"6","doi-asserted-by":"publisher","unstructured":"6) Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39 (11):3015-21. doi: 10.1161\/STROKEAHA.108.519942","DOI":"10.1161\/STROKEAHA.108.519942"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7) Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10 (7):618-25. doi: 10.1016\/S1474-4422(11)70108-9","DOI":"10.1016\/S1474-4422(11)70108-9"},{"key":"8","unstructured":"8) Macdonald RL, Wlodarczyk J, Mayer SA, et al. Safety profile of clazosentan: pooled analysis of CONSCIOUS trials. J Stroke Cerebrovasc Dis. 2013;22 (5):e352-60."},{"key":"9","unstructured":"9) Koyama T, Domen K, Okita M. Early rehabilitation using mobilization and exercise improves activities of daily living and functional recovery in patients with subarachnoid hemorrhage. Top Stroke Rehabil. 2014;21 (2):140-5."},{"key":"10","unstructured":"10) Fujimura M, Tominaga T. Japanese phase III trial of clazosentan after SAH. Neurol Med Chir (Tokyo). 2014;54 (5):362-9."},{"key":"11","doi-asserted-by":"publisher","unstructured":"11) Vergouwen MDI, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41 (10):2391-5. doi: 10.1161\/STROKEAHA.110.589275","DOI":"10.1161\/STROKEAHA.110.589275"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Bernhardt J, Dewey H, Thrift A, et al. A very early rehabilitation trial for stroke (AVERT): phase II safety and feasibility. Stroke. 2008;39 (2):390-6. doi: 10.1161\/STROKEAHA.107.492363","DOI":"10.1161\/STROKEAHA.107.492363"},{"key":"13","unstructured":"13) Kisanuki YY, Chen Y, Kurihara H, et al. Clazosentan: a selective endothelin A receptor antagonist in subarachnoid hemorrhage. Expert Opin Investig Drugs. 2009;18 (12):1815-25."},{"key":"14","unstructured":"14) Lindner C, Freund W, Fischer G, et al. Increased endothelin-1 concentrations in CSF and plasma in patients with SAH. Neurosurgery. 1991;29 (4):535-42."},{"key":"15","unstructured":"15) Kazumata K, Kamiyama H, Ishikawa T, et al. Role of endothelin-1 in the pathophysiology of cerebral vasospasm after subarachnoid hemorrhage. J Neurol Surg. 1993;79 (4):558-63."},{"key":"16","doi-asserted-by":"publisher","unstructured":"16) Macdonald RL, Higashida RT, Keller E, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43 (6):1463-9. doi: 10.1161\/STROKEAHA.111.648980","DOI":"10.1161\/STROKEAHA.111.648980"},{"key":"17","unstructured":"17) Dodd WS, Laurent D, Sim SY, et al. Clazosentan for the prevention of vasospasm and DCI: a meta-analysis. Neurosurgery. 2021;88 (4):732-41."},{"key":"18","unstructured":"18) Kohan DE, Inscho EW, Wesson D, et al. Physiology and pathophysiology of endothelin in the kidney. Am J Physiol Ren Physiol. 2011;301 (4):F841-56."},{"key":"19","unstructured":"19) Dhaun N, Goddard J, Webb DJ. Endothelin-1 and the kidney-beyond blood pressure. Nat Rev Nephrol. 2006;2 (1):10-20."},{"issue":"10","key":"20","first-page":"984","volume":"16","author":"JP Nicholson","year":"2000","unstructured":"20) Nicholson JP, Wolmarans MR, Park GR. Hypoalbuminemia: pathophysiologic and clinical significance. Nutrition. 2000;16 (10):984-8.","journal-title":"Nutrition","ISSN":"https:\/\/id.crossref.org\/issn\/0899-9007","issn-type":"print"},{"issue":"3","key":"21","first-page":"655","volume":"36","author":"J Bernhardt","year":"2005","unstructured":"21) Bernhardt J, Dewey H, Thrift A, et al. Physical activity in acute stroke: safety and feasibility. Stroke. 2005;36 (3):655-9.","journal-title":"Stroke","ISSN":"https:\/\/id.crossref.org\/issn\/0039-2499","issn-type":"print"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22) Mutoh T, Aono H, Seto W, et al. Cardiopulmonary events of the elderly (\u226575 years) during clazosentan therapy after subarachnoid hemorrhage: A retrospective study from a tertiary Stroke Center in Japan. Medicina (Kaunas). 2024;60 (1):185. doi: 10.3390\/medicina60010185","DOI":"10.3390\/medicina60010185"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23) Liu-DeRyke X, Rhoney DH. Cerebral vasospasm after aneurysmal subarachnoid hemorrhage: an overview of pharmacologic management. Pharmacotherapy. 2006;26 (2):182-203. doi: 10.1592\/phco.26.2.182","DOI":"10.1592\/phco.26.2.182"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24) Kajiwara S, Kawano T, Hasegawa Y, et al. Impact of clazosentan on vasospasm reduction and functional recovery after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2025;65 (1):29-36. doi: 10.2176\/jns-nmc.2024-0204","DOI":"10.2176\/jns-nmc.2024-0204"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25) Karic T, R\u00f8e C, Nordenmark TH, et al. Impact of early mobilization and rehabilitation on global functional outcome one year after aneurysmal subarachnoid hemorrhage. J Rehabil Med. 2016;48 (8):676-82. doi: 10.2340\/16501977-2121","DOI":"10.2340\/16501977-2121"},{"key":"26","unstructured":"26) Fujimoto Y, Teranishi K, Takano H, et al. Clinical outcomes of clazosentan administration for the prevention of cerebral vasospasm after subarachnoid hemorrhage: a multicenter retrospective study. Neurol Med Chir (Tokyo). 2024;64 (4):181-8. doi: 10.2176\/nmc.oa.2023-0273"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27) AVERT Trial Collaboration Group. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet. 2015;386 (9988):46-55. doi: 10.1016\/S0140-6736(15)60690-0","DOI":"10.1016\/S0140-6736(15)60690-0"}],"container-title":["Neurologia medico-chirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/65\/12\/65_2025-0190\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T04:07:11Z","timestamp":1766203631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/65\/12\/65_2025-0190\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2025-0190","relation":{},"ISSN":["0470-8105","1349-8029"],"issn-type":[{"type":"print","value":"0470-8105"},{"type":"electronic","value":"1349-8029"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"2025-0190"}}